Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

NUVB

Nuvation Bio Inc

Nov 20 • 04:00PM ET

7.01

-0.14 -1.96 %

Healthcare • Biotechnology • USA • NYSE

Peers: GILD AMGN REGN VRTX BIIB MRNA BMY PFE LLY SNY

| Held by: VTI IWM IWN VXF IBB SCHA VTWO XPH AVSC IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.64	Insider Own	32.41%	Shs Outstand	341.76M	Perf Week	49.47%
Market Cap	2.41B	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.44%	Shs Float	232.39M	Perf Month	68.92%
Enterprise Value	2.07B	PEG	-	EPS next Q	-0.10	Inst Own	53.84%	Short Float	29.13%	Perf Quarter	141.72%
Income	-217.48M	P/S	90.10	EPS this Y	71.41%	Inst Trans	4.07%	Short Ratio	8.06	Perf Half Y	211.56%
Sales	26.75M	P/B	7.37	EPS next Y	13.08%	ROA	-37.08%	Short Interest	67.69M	Perf YTD	163.53%
Book/sh	0.95	P/C	4.39	EPS next 5Y	52.23%	ROE	-52.49%	52W High	7.35 -4.63%	Perf Year	173.83%
Cash/sh	1.60	P/FCF	-	EPS past 3/5Y	-68.86% -49.14%	ROIC	-41.78%	52W Low	1.54 355.19%	Perf 3Y	265.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	48.95%	Volatility	17.46% 11.60%	Perf 5Y	-30.94%
Dividend TTM	-	EV/Sales	77.36	EPS Y/Y TTM	70.51%	Oper. Margin	-870.98%	ATR (14)	0.56	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.39	Sales Y/Y TTM	1137.19%	Profit Margin	-813.07%	RSI (14)	75.73	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.48	EPS Q/Q	-8.23%	SMA20	35.73%	Beta	1.49	Target Price	10.38
Payout	-	Debt/Eq	0.64	Sales Q/Q	1704.68%	SMA50	67.22%	Rel Volume	2.41	Prev Close	7.15
Employees	220	LT Debt/Eq	0.60	Earnings	Nov 03 AMC	SMA200	156.00%	Avg Volume	8.39M	Price	7.01
IPO	Aug 26, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.16% 98.51%	Trades		Volume	20,224,244	Change	-1.96%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-19-25	Initiated	B. Riley Securities	Buy	$12
Sep-30-25	Initiated	Jefferies	Buy	$10
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform	$6
Mar-27-24	Upgrade	Jefferies	Hold → Buy	$1.40 → $10
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy	$5
Jan-06-23	Downgrade	Jefferies	Buy → Hold	$5 → $2
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$8 → $2.50
May-04-22	Initiated	H.C. Wainwright	Buy	$14
Oct-15-21	Resumed	BTIG Research	Buy	$16
Apr-06-21	Initiated	RBC Capital Mkts	Outperform	$15
Mar-08-21	Initiated	Wedbush	Outperform	$20
Mar-08-21	Initiated	Jefferies	Buy	$20
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	BTIG Research	Buy	$16
Mar-08-21	Initiated	BMO Capital Markets	Outperform	$16

Show Previous Ratings

Today 06:27AM	Nuvation Bio (NUVB) Jumps to 3-Year High on Bullish Coverage (Insider Monkey)
Nov-18-25 06:17AM	Nuvation Bio Inc. (NUVB) is a Buy at H.C. Wainwright on Cancer Drug Development Progress (Insider Monkey)
Nov-07-25 09:34PM	Is Nuvation Bio (NUVB) One of the Best American Penny Stocks to Buy? (Insider Monkey) -5.78%
Nov-04-25 12:01AM	Nuvation Bio Inc (NUVB) Q3 2025 Earnings Call Highlights: Strong IBTROZI Launch and Robust ... (GuruFocus.com) -6.58%
Nov-03-25 05:55PM	Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Loading…
04:05PM	Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Oct-31-25 09:22AM	Nuvation Bio Inc (NUVB) Q3 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-30-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
Oct-29-25 05:25PM	MiMedx (MDXG) Tops Q3 Earnings and Revenue Estimates (Zacks)
Oct-23-25 07:30AM	Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma (Business Wire) +5.78%
Oct-20-25 04:05PM	Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 (Business Wire) +8.50% +13.78%
Oct-08-25 01:02PM	Nuvation Bio Inc. (NUVB): A Bull Case Theory (Insider Monkey)
08:55AM	NYSE Content Advisory: Pre-Market Update + The AW Playmaker Awards Take the Stage at 11 Wall Street (PR Newswire)
Sep-30-25 11:33AM	Why Nuvation Bio Stock Is Skyrocketing Today (Motley Fool) +14.91%
07:30AM	Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer (Business Wire)
07:30AM	Loading…
Sep-19-25 07:30AM	Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Sep-07-25 06:00AM	Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer (Business Wire)
Aug-27-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
09:55AM	Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB) (Insider Monkey)
Aug-07-25 08:45AM	Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:30AM	Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Aug-06-25 05:15PM	Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-05-25 08:00AM	Nuvation Bio To Present New Data on IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (Business Wire)
Aug-01-25 06:46AM	Nuvation Bio (NUVB)'s Taletrectinib Selected as Preferred Agent for Cancer Treatment (Insider Monkey) -5.51%
Jul-24-25 04:05PM	Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025 (Business Wire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire)
Jul-09-25 12:00PM	All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy (Zacks) +15.61%
Jun-29-25 03:00AM	Two Beaten-Down Biotech Stocks See Big Insider Buys (Barrons.com)
Jun-24-25 05:33PM	RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating (Insider Monkey) -8.29%
07:00AM	Loading…
07:00AM	Nuvation Bio Announces National Comprehensive Cancer Network Adds Taletrectinib (IBTROZI) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers (Business Wire)
Jun-20-25 02:25PM	Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now? (Barchart) +10.06%
Jun-11-25 01:20PM	U.S. Food and Drug Administration Approves Nuvation Bios IBTROZI (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer (Business Wire) -13.04%
12:52AM	FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche (BioPharma Dive)
May-21-25 04:05PM	Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting (Business Wire) -6.45% +10.84%
May-13-25 04:05PM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025 (Business Wire)
May-12-25 04:05PM	Nuvation Bio to Participate in Upcoming Investor Conferences (Business Wire)
May-09-25 01:00PM	Nuvation Bio Inc (NUVB) Q1 2025 Earnings Call Highlights: Promising Developments and Strategic Moves (GuruFocus.com)
04:31AM	Nuvation Bio Inc. (NUVB): Among Billionaire David Abrams' Stock Picks with Huge Upside Potential (Insider Monkey)
May-07-25 06:35PM	Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
09:07AM	Nuvation Bio: A Real Shot To Move The Needle In Lung Cancer Subtypes (Seeking Alpha)
May-01-25 04:05PM	Nuvation Bio to Present at The Citizens Life Sciences Conference (Business Wire) +8.37%
Apr-22-25 04:05PM	Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025 (Business Wire)
Apr-16-25 10:03AM	Is Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.93%
Apr-13-25 05:40PM	Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
Apr-09-25 09:43AM	Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple (Insider Monkey) +7.83%
Apr-02-25 08:00AM	Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference (Business Wire)
Mar-25-25 04:45PM	Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025 (Business Wire)
08:00AM	Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025 (Business Wire)
Mar-17-25 03:47PM	Is Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts? (Insider Monkey)
Mar-09-25 04:11AM	Nuvation Bio Inc. (NUVB): Among the Best NYSE Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-06-25 04:30PM	Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (Business Wire) +6.88%
Mar-04-25 05:11AM	Nuvation Bio secures $250m for taletrectinib commercialisation (Pharmaceutical Technology)
Mar-03-25 08:35AM	Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners (Business Wire) -7.61%
Feb-24-25 08:00AM	Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -5.88%
Feb-03-25 08:00AM	Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Jan-06-25 04:05PM	Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +14.44%
08:00AM	Nuvation Bio Receives Approval from Chinas National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-30-24 03:00PM	Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey) -5.07%
Dec-23-24 08:00AM	U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bios New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer (Business Wire)
Dec-20-24 07:10AM	Innovent Receives Approval of DOVBLERON (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration (PR Newswire)
Nov-26-24 08:00AM	Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-12-24 04:05PM	Nuvation Bio to Present at the Jefferies London Healthcare Conference (Business Wire)
Nov-06-24 04:05PM	Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) +9.48%
01:11AM	Nuvation Bio Inc. (NUVB): Promising Penny Stock with Strong Oncology Pipeline (Insider Monkey)
Oct-16-24 09:06AM	Is Nuvation Bio Inc. (NUVB) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey) +10.30%
Oct-14-24 11:51AM	Is Nuvation Bio Inc. (NUVB) Hedge Funds Favorite Penny Stock? (Insider Monkey)
Oct-09-24 08:02AM	Growing Confidence in Nuvation Bio, Inc. (NUVB) as Hedge Fund Holdings Increase to 35 (Insider Monkey)
Oct-07-24 04:05PM	Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer (Business Wire) -9.96%
Oct-02-24 02:02AM	Navigating Legal Uncertainty: Nuvation Bio Inc.s Chinese Operations and the Shifting Landscape of Chinas Civil Law System (TipRanks)
Sep-14-24 03:05AM	Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 (Business Wire)
Sep-09-24 08:00AM	Nuvation Bio to Present at the Cantor Global Healthcare Conference (Business Wire) +6.45%
Aug-06-24 06:32AM	Nuvation Bio pauses oncology drug after Phase I efficacy and safety analysis (Clinical Trials Arena) -6.29%
Aug-05-24 02:27PM	Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data (Benzinga) -5.36%
08:00AM	Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Jul-23-24 04:05PM	Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib (Business Wire) +10.06%
Jun-02-24 01:13AM	Innovent Announces TaletrectinibROS1 InhibitorUpdated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting (PR Newswire)
Jun-01-24 08:10AM	Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting (Business Wire)
May-29-24 04:05PM	Nuvation Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-14-24 10:54PM	NUVB Stock Earnings: Nuvation Bio Beats EPS for Q1 2024 (InvestorPlace)
05:08PM	Nuvation Bio Q1 Loss Narrows; Shares Fall After Hours (MT Newswires)
04:05PM	Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update (Business Wire)
Apr-24-24 10:01AM	Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (Business Wire)
Apr-10-24 04:01PM	Nuvation Bio Completes Acquisition of AnHeart Therapeutics (Business Wire) -5.57%
Mar-28-24 08:00AM	Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer (Business Wire) -8.31%
Mar-25-24 07:00AM	Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (Business Wire)
Mar-14-24 04:05PM	Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire) -9.13%
08:45AM	Biotech's Role in Addressing the Pancreatic Cancer Emergency (PR Newswire)
Mar-08-24 12:00PM	Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know (Zacks)
Feb-29-24 04:01PM	Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (Business Wire) -5.08% +19.25%
Feb-27-24 03:30AM	12 Best Medical Stocks to Buy Under $10 (Insider Monkey)
Jan-08-24 04:10PM	Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors (Business Wire)
04:05PM	Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors (Business Wire)
Nov-13-23 04:05PM	Nuvation Bio Announces Departure of Chief Financial Officer (Business Wire) +5.47%
Nov-02-23 06:04PM	Nuvation Bio Inc (NUVB) Reports Q3 2023 Financial Results (GuruFocus.com) +10.34% +5.47%
04:10PM	Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Aug-03-23 04:10PM	Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-13-23 09:45AM	15 Best Penny Stocks To Buy Now (Insider Monkey)
Jun-01-23 04:05PM	Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board (Business Wire)

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GARY HATTERSLEY	Officer	Nov 20 '25	Proposed Sale	7.23	369,051	2,667,132		Nov 20 04:12 PM
DONGFANG LIU	Officer	Nov 20 '25	Proposed Sale	7.00	20,000	140,074		Nov 20 04:07 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Option Exercise	1.87	15,000	28,050	30,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 19 '25	Sale	5.10	15,000	76,552	18,000	Nov 19 04:47 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	Nov 17 '25	Sale	4.76	15,000	71,475	15,000	Nov 19 04:47 PM
DONGFANG LIU	Officer	Nov 19 '25	Proposed Sale	5.10	15,000	76,552		Nov 19 04:18 PM
DAVID HANLEY	Officer	Nov 19 '25	Proposed Sale	7.14	200,000	1,427,680		Nov 19 04:09 PM
DONGFANG LIU	Officer	Nov 17 '25	Proposed Sale	4.76	15,000	71,475		Nov 17 04:12 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Option Exercise	1.74	100,000	174,000	100,000	Oct 29 04:24 PM
Hattersley Gary	CHIEF SCIENTIFIC OFFICER	Oct 27 '25	Sale	5.02	100,000	502,460	0	Oct 29 04:24 PM
GARY HATTERSLEY	Officer	Oct 27 '25	Proposed Sale	4.85	100,000	485,000		Oct 27 04:26 PM
Markel Stacy	CHIEF PEOPLE OFFICER	Jun 18 '25	Buy	1.71	10,000	17,100	29,591	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 17 '25	Buy	1.79	4,000	7,160	9,902	Jun 18 04:05 PM
Sauvage Philippe	Chief Financial Officer	Jun 16 '25	Buy	1.83	3,300	6,056	5,902	Jun 18 04:05 PM
Sjogren Colleen	Chief Commercial Officer	Jun 16 '25	Buy	1.81	50,000	90,350	81,000	Jun 18 04:05 PM
Wentworth Kerry	CHIEF REGULATORY OFFICER	Jun 16 '25	Buy	1.79	50,000	89,740	50,000	Jun 18 04:05 PM
Hung David	PRESIDENT AND CEO	Jun 16 '25	Buy	1.79	500,000	893,500	59,281,054	Jun 18 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Option Exercise	1.94	20,000	38,800	32,000	May 06 04:05 PM
Liu Dongfang	CHIEF MEDICAL OFFICER	May 02 '25	Sale	2.50	20,000	50,024	12,000	May 06 04:05 PM
DONGFANG LIU	Officer	May 02 '25	Proposed Sale	2.27	20,000	45,400		May 02 04:23 PM
Hung David	PRESIDENT AND CEO	Apr 07 '25	Buy	1.62	300,000	487,500	58,781,054	Apr 08 09:30 PM
Hung David	PRESIDENT AND CEO	Apr 04 '25	Buy	1.66	200,000	332,720	58,481,054	Apr 08 09:30 PM
Mashal Robert	Director	Apr 01 '25	Buy	1.67	100,000	166,985	200,000	Apr 03 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

NUVB

Nuvation Bio Inc

Upgrade your FINVIZ experience